P. Laurent-;-astrazeneca, . Boerhingher-ingelheim, . Lilly, R. Merck-serono, . Sanofi et al., Zaanan Study supervision: P. Laurent-Puig, V. Taly, A. Zaanan Grant Support This work was supported by the Minist ere de l'Enseignement Sup erieur et de la Recherche, the Universit e Paris-Descartes, the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Sant e et de la Recherche M edicale (INSERM), the Institut National du Cancer (INCA, n 2009-1-RT-03-US-1 and 2009-RT-03-UP5-1), the Association pour la recherche contre le cancer (ARC, no. SL220100601375), the Agence Nationale de la Recherche

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, pp.359-86, 2015.

E. Van-cutsem, A. Cervantes, R. Adam, A. Sobrero, J. H. Van-krieken et al., ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, vol.27, pp.1386-422, 2016.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-275, 2009.

M. R. Sharma, M. L. Maitland, and M. J. Ratain, RECIST: no longer the sharpest tool in the oncology clinical trials toolbox-point, Cancer Res, vol.72, pp.5145-5154, 2012.

B. Zhao, S. M. Lee, H. J. Lee, Y. Tan, J. Qi et al., Variability in assessing treatment response: metastatic colorectal cancer as a paradigm, Clin Cancer Res, vol.20, pp.3560-3568, 2014.

M. J. Duffy, A. Van-dalen, C. Haglund, L. Hansson, R. Klapdor et al., Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines, Eur J Cancer, vol.39, pp.718-745, 2003.

M. J. Duffy, A. Van-dalen, C. Haglund, L. Hansson, E. Holinski-feder et al., Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use, Eur J Cancer, vol.43, pp.1348-60, 2007.

H. Sorbye and O. Dahl, Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines, J Clin Oncol, vol.21, pp.4466-4473, 2003.

M. J. Goldstein and E. P. Mitchell, Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer, Cancer Invest, vol.23, pp.338-51, 2005.

J. Maurel and A. Postigo, Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice, Curr Cancer Drug Targets, vol.15, pp.703-718, 2015.

C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, pp.224-248, 2014.

S. J. Dawson, D. W. Tsui, M. Murtaza, H. Biggs, O. M. Rueda et al., Analysis of circulating tumor DNA to monitor metastatic breast cancer, N Engl J Med, vol.368, pp.1199-209, 2013.

K. Ray, Colorectal cancer: Liquid biopsy enables real-time monitoring of molecular alterations in CRC, Nat Rev Gastroenterol Hepatol, vol.12, p.372, 2015.

J. Tabernero, H. J. Lenz, S. Siena, A. Sobrero, A. Falcone et al., Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial, Lancet Oncol, vol.16, pp.937-985, 2015.

J. Tie, I. Kinde, Y. Wang, H. L. Wong, J. Roebert et al., Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, vol.26, pp.1715-1737, 2015.

L. A. Diaz, R. T. Williams, J. Wu, I. Kinde, J. R. Hecht et al., The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, vol.486, pp.537-577, 2012.

P. Laurent-puig, D. Pekin, C. Normand, S. K. Kotsopoulos, P. Nizard et al., Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy, Clin Cancer Res, vol.21, pp.1087-97, 2015.

G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, A. Cassingena et al., Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat Med, vol.21, pp.795-801, 2015.

F. Diehl, M. Li, D. Dressman, Y. He, D. Shen et al., Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci U S A, vol.102, pp.16368-73, 2005.

H. Schwarzenbach, D. S. Hoon, and K. Pantel, Cell-free nucleic acids as biomarkers in cancer patients, Nat Rev Cancer, vol.11, pp.426-463, 2011.

V. Taly, D. Pekin, A. El-abed, and P. Laurent-puig, Detecting biomarkers with microdroplet technology, Trends Mol Med, vol.18, pp.405-421, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02299585

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, pp.1722-1753, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

L. A. Diaz and A. Bardelli, Liquid biopsies: genotyping circulating tumor DNA, J Clin Oncol, vol.32, pp.579-86, 2014.

S. Garrigou, G. Perkins, F. Garlan, C. Normand, A. Didelot et al., A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker, Clin Chem, vol.62, pp.1129-1168, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02295782

M. Li, W. D. Chen, N. Papadopoulos, S. N. Goodman, N. C. Bjerregaard et al., Sensitive digital quantification of DNA methylation in clinical samples, Nat Biotechnol, vol.27, pp.858-63, 2009.

E. O. Ogundimu, D. G. Altman, and G. S. Collins, Adequate sample size for developing prediction models is not simply related to events per variable, J Clin Epidemiol, vol.76, pp.175-82, 2016.

A. , C. Pantel, and K. , Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy, Cancer Discov, vol.6, pp.479-91, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01872958

K. L. Spindler, A. L. Appelt, N. Pallisgaard, R. F. Andersen, I. Brandslund et al., Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer, Int J Cancer, vol.135, pp.2984-91, 2014.

J. P. Roperch, R. Incitti, S. Forbin, F. Bard, H. Mansour et al., Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for bloodbased diagnosis of colorectal cancer, Clin Cancer Res Fanny Garlan, vol.13, pp.5416-5425, 2013.